Literature DB >> 21637316

Clinical trials: Insufficient data on glucocorticoid use in RA trials.

Rieke H E Alten.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21637316     DOI： 10.1038/nrrheum.2011.70

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis.

Authors:  Monica Todoerti; Carlo Alberto Scirè; Nicola Boffini; Serena Bugatti; Carlomaurizio Montecucco; Roberto Caporali
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

2.  Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.

Authors:  Niels Graudal; Gesche Jürgens
Journal:  Arthritis Rheum       Date:  2010-10

Review 3.  Information on glucocorticoid therapy in the main studies of biological agents.

Authors:  Vincent André; Benoît le Goff; Christophe Leux; Marianne Pot-Vaucel; Yves Maugars; Jean-Marie Berthelot
Journal:  Joint Bone Spine       Date:  2011-02-22       Impact factor: 4.929

4.  Dose-related patterns of glucocorticoid-induced side effects.

Authors:  D Huscher; K Thiele; E Gromnica-Ihle; G Hein; W Demary; R Dreher; A Zink; F Buttgereit
Journal:  Ann Rheum Dis       Date:  2008-08-06       Impact factor: 19.103

5.  Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study.

Authors:  I Hafström; K Albertsson; A Boonen; D van der Heijde; R Landewé; B Svensson
Journal:  Ann Rheum Dis       Date:  2008-04-17       Impact factor: 19.103

6.  Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density.

Authors:  B Tengstrand; E Larsson; L Klareskog; I Hafström
Journal:  Scand J Rheumatol       Date:  2007 Sep-Oct       Impact factor: 3.641

7.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2008-02

8.  Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.

Authors:  Rieke Alten; Christof Pohl; Ernest H Choy; Robin Christensen; Daniel E Furst; Sarah E Hewlett; Amye Leong; James E May; Tessa C Sanderson; Vibeke Strand; Thasia G Woodworth; Clifton O Bingham
Journal:  J Rheumatol       Date:  2011-08       Impact factor: 4.666

9.  Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial.

Authors:  T Pincus; C J Swearingen; G Luta; T Sokka
Journal:  Ann Rheum Dis       Date:  2008-12-15       Impact factor: 19.103
  9 in total
  1 in total

Review 1.  [Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis].

Authors:  Gernot Keyßer
Journal:  Z Rheumatol       Date:  2021-03-11       Impact factor: 1.372
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.